

Pharmacy Communications

Massachusetts



Date: February 29, 2024

To: All WellSense Providers

From: WellSense Health Plan

Subject: **Pharmacy Benefit Updates**

Product: MassHealth Qualified Health Plans Senior Care Options

Pharmacy Benefit Updates

As a result of updates to MassHealth's uniform formulary, we're making multiple pharmacy benefit updates:

Restricted to Medical Billing

The following drugs will be restricted to medical billing, effective May 6, 2024:

- Elrexfio (elranatamab-bcmm)
- Izervay (avacincaptad pegol)
- Mylotarg (gemtuzumab ozogamicin)
- Portrazza (necitumumab)
- Rybrevant (amivantamab-vmjw)
- Talvey (talquetamab-tgvs)
- Veopoz (pozelimab-bbfg)
- Zepzelca (lurbinectedin)
- Zilretta (triamcinolone extended-release injectable suspension)

Updated Clinical Policies

The following clinical policies have been updated, effective May 6, 2024:

Pharmacy Communications

Massachusetts

- Alzheimer's Agents
- Androgen Therapy
- Anti-Allergy and Anti-Inflammatory Agents (Ophthalmic)
- Antibiotics, oral
- Anticonvulsant
- Antidepressants
- Antidiabetic Agents (Non-insulin and Combination)
- Antiemetics
- Antifungals (Topical)
- Anti-Hemophilia Gene Therapy Agents
- Antimyasthenic/Cholinergic agents
- Anti-Obesity Agents
- Antioxidant agents
- Antiparkinsonian Agents
- Antipsychotics
- Bowel Preparation Agents
- Cardiovascular Agents
- Colorectal Cancer Agents
- Complement Inhibitors and Miscellaneous Immunosuppressive Agents
- Continuous Glucose Monitoring Products
- Continuous Subcutaneous Insulin Infusion
- Corticosteroids (Oral)
- Daprodustat (Jesduvroq)
- Diabetic Testing Supplies
- Dronabinol (Marinol Syndros)
- elivaldogene Autotemcel (Skysona)
- Gastrointestinal Agents (H2 Antagonists, PPIs and Miscellaneous Agents)
- Gemtuzumab Ozogamicin (Mylotarg)
- Glaucoma Agents
- Hereditary Angioedema Agents
- Hyaluronate (Injectable)
- Kinase Inhibitors
- Lung Cancer Agents
- Melanoma Agents
- NSAIDs (Topical)
- Oncology Immunotherapies

Pharmacy Communications

Massachusetts

- Osteoporosis Agents and Miscellaneous Calcium Regulators
- palovarotene (Sohonos)
- Pediatric Behavioral Health Initiative
- pexidartinib (Turalio)
- Potassium Binding Agents
- Prostate Cancer
- T-Cell Immunotherapies
- teprotumumab (Tepezza)
- tesamorelin (Egrifta SV)
- Thrombocytopenic Agents
- Triamcinolone (Zilretta)
- triclabendazole (Egaten)
- Tropomyosin Receptor Kinase (TRK) Inhibitors
- Vaccines
- Wound Care

Brand-preferred Product Status Change

The following drugs will change brand-preferred product status, effective May 6, 2024:

- Emflaza (deflazacort) - brand preferred
- Farxiga (dapagliflozin) - brand preferred
- Fortesta (testosterone 2% gel pump) - no longer brand preferred
- Isentress (raltegravir) - brand preferred
- Kazano (alogliptin/metformin) - no longer brand preferred
- Luzu (luliconazole) - no longer brand preferred
- Marinol (dronabinol) - brand preferred
- Nesina (alogliptin) - no longer brand preferred
- Oseni (alogliptin/pioglitazone) - no longer brand preferred
- Oxistat (oxiconazole cream) - no longer brand preferred
- Pennsaid (diclofenac topical solution) - no longer brand preferred
- Pristiq (desvenlafaxine succinate extended-release) - no longer brand preferred
- Rapamune (sirolimus solution) - no longer brand preferred
- Restasis (cyclosporine 0.05% ophthalmic emulsion) - brand preferred
- Sprycel (dasatinib) - brand preferred

Pharmacy Communications

Massachusetts

- Toujeo (insulin glargine) – brand preferred
- Welchol (colesevelam) – no longer brand preferred
- Xigduo XR (dapagliflozin/metformin extended-release) – brand preferred

Prior Authorization

The following drugs will require prior authorization, effective May 6, 2024:

- Agamree (vamorolone)
- Anzemet (dolasetron)
- Fruzaqla (fruquintinib)
- Jesduvroq (daprodustat)
- Likmez (metronidazole suspension)
- Motpoly XR (locosamide extended-release capsule)
- Namzaric
- Sohonos (palovarotene)
- Suflave (polyethylene glycol/sodium sulfate/potassium chloride/magnesium sulfate/sodium chloride)
- Tolnaftate Liquid
- Vanflyta (quizartinib)
- Vevye (cyclosporine 0.1% ophthalmic solution)
- Voquezna (vonoprazan)
- Xdemvy (lotilaner)
- Zepbound (tirzepatide)
- Vyjuvek (beremagene geperpavec-svdt)

Click [here](#) for the most recent updates to MassHealth’s drug list.